Lista de obras - Marcel H.A. Muskiet - Dominio Público Uruguay

ACE-I vs. ARB for blood pressure control in diabetic kidney disease

artículo científico publicado en 2014

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

artículo científico publicado en 2016

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2016

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

artículo científico publicado en 2015

Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance

scientific article published on 26 August 2019

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

artículo científico publicado en 2016

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

artículo científico publicado en 2015

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

artículo científico publicado en 2019

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

scientific article published on 10 August 2014

Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.

artículo científico publicado en 2017

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

artículo científico publicado en 2015

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

artículo científico publicado en 2020

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial

artículo científico publicado en 2014

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism ⬇️

artículo científico publicado el 17 de noviembre de 2010

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

artículo científico publicado en 2018

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

artículo científico publicado en 2020

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

artículo científico publicado en 2020

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

artículo científico publicado en 2020

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

artículo científico publicado en 2019

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556

scientific article published on 20 August 2019

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

artículo científico publicado en 2015

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

artículo científico publicado en 2015

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

artículo científico publicado en 2017

GLP-1 based therapies: clinical implications for gastroenterologists.

artículo científico publicado en 2016

GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials

artículo científico publicado en 2019

GLP-1 receptor agonists, CKD, and eGFR trajectory

scientific article published on 01 October 2018

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

artículo científico publicado en 2016

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

artículo científico publicado en 2017

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

artículo científico publicado en 2016

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

artículo científico publicado en 2020

Incretin-based drugs and renoprotection—is hyperfiltration key?

artículo científico publicado en 2015

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

scientific article published on 29 October 2019

Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"

artículo científico publicado en 2015

Liraglutide and Renal Outcomes in Type 2 Diabetes

artículo científico publicado en 2017

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

artículo científico publicado en 2018

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

scientific article published on 03 October 2018

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.

artículo científico publicado en 2011

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

artículo científico publicado en 2020

New pharmacological strategies for protecting kidney function in type 2 diabetes

artículo científico publicado en 2018

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

artículo científico publicado en 2016

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

artículo científico publicado en 2017

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

artículo científico publicado en 2015

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

artículo científico

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

artículo científico publicado en 2016

Renal outcomes in CVOTs: keep calm and carry on

artículo científico publicado en 2018

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

artículo científico publicado en 2019

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

article

Renoprotection in LEADER and EMPA-REG OUTCOME

artículo científico publicado en 2016

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance

artículo científico publicado en 2017

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

artículo científico publicado en 2017

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

artículo científico publicado en 2018

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise

artículo científico publicado en 2020

SGLT2 inhibition: a new era in renoprotective medicine?

artículo científico publicado en 2017

SGLT2 inhibitors: expanding their Empire beyond diabetes

artículo científico publicado en 2020

Should dietary SFA be exchanged for linoleic acid?

scientific article published on 01 October 2012

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

artículo científico publicado en 2016

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

artículo científico publicado en 2013

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

scientific article published on 10 October 2019

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

artículo científico publicado en 2016

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

artículo científico publicado en 2014

Understanding EMPA-REG OUTCOME

artículo científico publicado en 2015

Lista de obras de Marcel H.A. Muskiet

ACE-I vs. ARB for blood pressure control in diabetic kidney disease

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism ⬇️

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

GLP-1 based therapies: clinical implications for gastroenterologists.

GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials

GLP-1 receptor agonists, CKD, and eGFR trajectory

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

Incretin-based drugs and renoprotection—is hyperfiltration key?

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"

Liraglutide and Renal Outcomes in Type 2 Diabetes

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

New pharmacological strategies for protecting kidney function in type 2 diabetes

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Renal outcomes in CVOTs: keep calm and carry on

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

Renoprotection in LEADER and EMPA-REG OUTCOME

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise

SGLT2 inhibition: a new era in renoprotective medicine?

SGLT2 inhibitors: expanding their Empire beyond diabetes

Should dietary SFA be exchanged for linoleic acid?

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

Understanding EMPA-REG OUTCOME